Kenvue Inc. stock falls Monday, underperforms market
Kenvue Inc. (KVUE) stock declined by 1.36% on Monday, closing at $19.56, despite a strong performance by the broader market. This drop ended a three-day winning streak for the company, with the S&P 500 and Dow Jones Industrial Average both seeing gains.
Kenvue stock keeps the focus on its consumer brands
Kenvue, a consumer health company, centers its business on a portfolio of household and personal care brands like Tylenol, Listerine, and Neutrogena, trading on the New York Stock Exchange. The company's stable business model, characterized by broad retail distribution and recurring demand, makes execution on margins, pricing, and brand support crucial. Investors evaluate Kenvue based on its consistent performance in the consumer-health sector and its ability to manage costs and maintain brand strength over time.
The Tylenol Extra Strength Caplets - Kenvue leans on a trusted classic for US pain relief
This article highlights how Tylenol Extra Strength Caplets, a well-established acetaminophen-based pain reliever, remains a core product for Kenvue (NYSE: KVUE). It details the product's dosage, target uses, safety warnings regarding liver damage, and its widespread availability and typical pricing in the US. The piece emphasizes Tylenol's brand heritage, its positioning as an alternative to NSAIDs, and its contribution to Kenvue's stable revenue stream despite competition from store-brand alternatives.
Hsbc Holdings PLC Has $88.23 Million Stock Position in Kenvue Inc. $KVUE
HSBC Holdings PLC significantly increased its stake in Kenvue Inc. by 31.8% in the fourth quarter, bringing its total holding to 5.1 million shares valued at $88.23 million. This increase makes HSBC one of several institutional investors to adjust their positions in Kenvue, which recently reported better-than-expected first-quarter earnings and declared a quarterly dividend. The consumer health company, a spin-off from Johnson & Johnson, currently holds a consensus "Hold" rating from analysts.
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Kenvue Inc. (NYSE:KVUE)
Rep. Gilbert Ray Cisneros, Jr. (Democratic-California) recently purchased shares of Kenvue Inc. (NYSE:KVUE) worth between $1,001 and $15,000 on June 16, 2026, as disclosed in a July 2nd filing. Kenvue reported strong quarterly results, exceeding analyst expectations for EPS and revenue, and offers a 4.2% dividend yield. Despite insider sales and a high payout ratio, analysts maintain a consensus "Hold" rating on the stock.
Kenvue beats first quarter profit estimates
Kenvue Inc. reported first-quarter results that surpassed Wall Street expectations, with adjusted earnings per share of $0.32 against an analyst consensus of $0.31, and revenue reaching $3.91 billion. Despite the positive financial performance, the company's stock experienced a slight dip in pre-market trading. Kenvue's Skin Health and Beauty segment led growth, though weak cold and flu seasons impacted its Self Care business.
Kenvue outlines its consumer health strategy. The company focuses on branded everyday products
Kenvue, a standalone consumer health company, is building its position by focusing on a portfolio of established over-the-counter and personal care brands that generate long-term, repeat-purchase demand. The company's strategy emphasizes scale, brand building, and innovation to maintain a diversified sales stream. Kenvue's model appeals to investors seeking businesses with broad customer bases and consistent demand for everyday health products.
KMB - Kimberly-Clark Corp Latest SEC Filings
This article provides detailed financial data and performance metrics for Kimberly-Clark Corp (KMB), including its latest stock close, market capitalization, income, sales, dividend information, and various financial ratios. It also lists insider ownership, institutional ownership, and short interest data, alongside performance metrics across different timeframes.
Kenvue focuses on consumer health portfolio as investors track long term growth prospects
Kenvue (ISIN US49177J1025) attracts investor interest due to its extensive portfolio of established consumer health brands, including over-the-counter medicines, self-care products, and personal care items. The company's business model is characterized by stable demand, brand loyalty, and diversification across multiple categories and markets, which helps mitigate economic fluctuations. Its focus on everyday healthcare needs, supported by global demographic trends like aging populations and rising health awareness, positions it for predictable cash flows and long-term growth, with less exposure to the regulatory and scientific risks associated with traditional pharmaceuticals.
Kenvue Inc. stock rises Thursday, outperforms market
Kenvue Inc. (KVUE) shares increased by 2.59% to $19.83 on Thursday, marking its third consecutive day of gains. This performance outpaced the broader market, as the S&P 500 Index remained largely unchanged and the Dow Jones Industrial Average rose by 1.14%.
Kenvue options trading jumps to 8,162 contracts
Kenvue Inc. (NYSE:KVUE) saw a significant increase in options trading, with 8,162 contracts traded by 2:01 p.m. New York time on Thursday. The majority, 7,896 contracts, were call options, with a notable concentration in the July 10, 2026 $20 call. Kenvue shares rose by 2.15% to $19.75, and InvestingPro analysis suggests the stock is undervalued with a fair value of $21.06 and an attractive PEG ratio of 0.44.
Top 5 Real Estate and Realty Stocks to Invest In According to Hedge Funds
This article identifies the top 5 real estate and realty stocks favored by hedge funds, providing a glimpse into their investment strategies. It highlights Mid-America Apartment Communities, Inc. (NYSE:MAA) as a key player, detailing its operational performance, development focus, and use of AI in its management platform. The piece offers a preview of a more extensive list and discusses notable performance metrics and strategic initiatives for the featured stock.
Citi Starts Coverage of Energy Vault Holdings, Inc. (NRGV)
Citi analysts have initiated coverage of Energy Vault Holdings, Inc. (NRGV) with a Neutral rating and a $5.25 price target, highlighting its capital-light model and exposure to power infrastructure and data center demand. The firm noted a desire for a more attractive entry point or better growth visibility before becoming more constructive. Additionally, Energy Vault recently acquired an 850 MW battery energy storage portfolio in Japan from BayWa r.e. AG, expanding its global asset base and strengthening its long-term growth strategy.
Here is What Analysts Think About Vistra Corp. (VST)
Vistra Corp. (VST) has received recent analyst attention, with Morgan Stanley lowering its price target to $210 while maintaining an "Overweight" rating. Bernstein initiated coverage with an "Outperform" rating and a $187 price target, highlighting the company's strong position in the shifting energy landscape due to its combined power plants and recent acquisition plans. Vistra is positioned as a key player in the energy transition, particularly for natural gas and clean energy infrastructure.
Morgan Stanley Lowers its Price Target on EQT Corporation (EQT)
Morgan Stanley has reduced its price target for EQT Corporation (NYSE:EQT) to $68 from $74, while maintaining an "Overweight" rating. This adjustment reflects lower energy prices following a US-Iran memorandum of understanding. EQT, a natural gas production company, also provided its second-quarter 2026 outlook, forecasting sales volumes and capital expenditures.
Kenvue (KVUE) Faces A $48.7 Billion Kimberly Clark Deal And Big Portfolio Questions
Kimberly-Clark plans to acquire Kenvue for $48.7 billion, leading to questions about Kenvue's future operations, capital allocation, and brand priorities within Kimberly-Clark's portfolio. Kenvue's stock has seen recent gains amid the acquisition news despite longer-term declines. Investors are now focused on the deal's integration plan, potential impact on margins, and future capital returns.
Form 4 Kenvue Inc For: 1 July By Investing.com
This article announces the filing of a Form 4 for Kenvue Inc. on July 1st. It provides no further details about the content of the Form 4 but is surrounded by typical financial news and market data from Investing.com. The information is presented as a stock market update.
Kenvue (KVUE) director adds 1,413 DSUs, Starboard-linked holdings at 27.3M shares
Kenvue Inc. director Jeffrey C. Smith reported an award of 1,413 Deferred Share Units (DSUs) and clarified his indirect holdings. Smith's total DSU balance is now 27,023.086 units, and through investment funds managed by Starboard Value LP, he is indirectly attributed 27,307,632 shares of Kenvue common stock, though he disclaims beneficial ownership beyond his pecuniary interest. The DSUs represent deferred cash compensation and will be settled in common stock upon his separation from service.
Should You Buy Kenvue Inc. (KVUE)’s Shares?
Kenvue Inc. (KVUE) shares are down 8.8% over the past year but up 10% year-to-date. Analysts have issued mixed ratings, with Citi cutting its price target to $19 and Barclays adjusting its target due to concerns about margin risk and input costs. Despite Highbridge Capital's investment, the article suggests other AI stocks might offer better upside potential.
Kenvue (KVUE) director Richard Allison granted 1,413 deferred share units as board fees
Kenvue Inc. director Richard E. Allison Jr. was granted 1,413 Deferred Share Units (DSUs) as part of his director compensation, which aligns his interests with long-term shareholder value. These DSUs represent the right to receive one share of Kenvue common stock each and will be settled after his separation from board service. Following this transaction, Allison holds a total of 49,797.671 DSUs, which also include dividend equivalents.
Should You Buy Kenvue Inc. (KVUE)’s Shares?
Kenvue Inc. (KVUE) shares are analyzed after a year of an 8.8% decline and a 10% year-to-date increase. Analysts like Citi and Barclays have adjusted price targets on KVUE, citing concerns over margin risk and higher input costs. Highbridge Capital, led by billionaire Glenn Dubin, has maintained a significant stake in KVUE, though the article suggests other AI stocks might offer greater upside potential.
hould You Buy Kenvue Inc. (KVUE)’s Shares?
Kenvue Inc. (NYSE:KVUE) shares have seen an 8.8% decline over the past year but are up 10% year-to-date. Analysts like Citi and Barclays have adjusted price targets, primarily due to concerns about margin risk and rising oil prices impacting input costs. Highbridge Capital has shown shifting interest in KVUE, holding shares in Q3 2023, then removing them, and re-establishing a significant stake in Q4 2025 and Q1 2026.
Kenvue Inc. stock rises Wednesday, outperforms market
Kenvue Inc. (KVUE) shares rose 1.15% to $19.33 on Wednesday, marking its second consecutive day of gains. This performance outperformed the broader market, as the S&P 500 Index (SPX) fell 0.22% and the Dow Jones Industrial Average (DJIA) fell 0.03% in what was a generally grim trading session.
The Neutrogena Oil-Free Acne Wash - Kenvue Inc. targets US teens with a steady skincare anchor
The Neutrogena Oil-Free Acne Wash is a core Kenvue product, widely available in US retailers at a price point of $7 to $10. It is positioned for teens and young adults with mild to moderate acne, offering a recognizable 2% salicylic acid gel cleanser that functions as a steady revenue generator for Kenvue Inc. within its broader skincare portfolio.
Piper Sandler Raises Price Target on Kimberly-Clark Corporation (KMB) on Productivity Gains
Piper Sandler has increased its price target for Kimberly-Clark Corporation (KMB) to $121 from $115, maintaining an Overweight rating. This adjustment reflects manageable cost headwinds due to strong productivity gains and a recent drop in oil prices. The new price target is based on 16x 2027 expected earnings per share, up from 15x, with Piper Sandler anticipating innovation to improve in the latter half of 2026.
Piper Sandler Raises Price Target on Kimberly-Clark Corporation (KMB) on Productivity Gains
Piper Sandler has increased its price target for Kimberly-Clark Corporation (KMB) to $121 from $115, maintaining an Overweight rating. This adjustment reflects manageable cost headwinds due to strong productivity gains and recent oil price drops. The firm noted that the updated price target is based on 16x 2027 expected earnings per share, an increase from the previous 15x, with innovation expected to pick up in the latter half of 2026.
Trading the Move, Not the Narrative: (KVUE) Edition
This article analyzes Kenvue Inc. (NASDAQ: KVUE) using AI models, identifying strong near and mid-term sentiment and compelling upside potential due to no resistance levels above the current price. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis and key support/resistance levels.
Listerine Smart Rinse from Kenvue Inc. - kid-focused mouthwash adds fluoride and flavor
Kenvue Inc. (NYSE: KVUE) markets Listerine Smart Rinse, a fluoride-containing mouthwash designed for children aged six and older. This product, featuring 0.02% sodium fluoride and kid-friendly flavors, aims to strengthen tooth enamel and build oral care habits. Widely available at major US retailers for around $4.49, it positions itself as an adjunct to brushing, distinguishing itself from adult Listerine with lower alcohol content and visual cues for cleaning effectiveness.
Kenvue surpasses 2025 plastic reduction target, falls short on recyclability
Kenvue, the parent company of brands like Listerine and Zyrtec, has exceeded its 2025 goal of reducing virgin plastic tonnage by 25%, achieving over 33% reduction from its 2020 baseline while setting a new target of 50% by 2030. However, the company fell short of its 2025 target to make all packaging recyclable or refillable, reaching only 67.1% last year, and now aims for 95% by 2030. Kenvue is implementing new strategies, including data-driven design and AI partnerships, to improve packaging sustainability and meet its long-term goals.
Kimberly-Clark’s 80% Payout Ratio: Balance Sheet Says Retirees Shouldn’t Be Scared
Kimberly-Clark's dividend looks stressed due to an 80% payout ratio and free cash flow barely covering dividends last year, raising concerns for income investors. However, an analysis of the balance sheet reveals the company is actively deleveraging, boosting shareholder equity, and operating cash flow surged 128% in Q1 2026. This financial strengthening combined with strategic acquisitions like Kenvue suggests the dividend is more secure than initially perceived, despite the high payout ratio.
KMB Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Kimberly-Clark Corp (KMB) financials, detailing its revenue breakdown, profitability margins, and competitor comparison. The largest revenue contributor is Baby and Child Care at 40.7% of total sales. KMB maintains a gross margin of 37.86%, an operating margin of 19.82%, and a net margin of 13.79%, with an ROE of 112.19%. The company's performance is benchmarked against competitors like KVUE and EL, highlighting its market position within the Personal Products industry.
Listerine Cool Mint Mouthwash from Kenvue Inc. - classic 500 ml formula stays a daily habit
This article examines Listerine Cool Mint Mouthwash, a classic 500 ml product by Kenvue Inc., detailing its formula and user experience. It highlights the mouthwash's role in daily oral hygiene and its contribution to Kenvue's steady revenue, also providing context on Kenvue's shares and market position. The piece covers product details, pricing, availability, and key facts about one of the leading global mouthwash brands.
Are Consumer Staples Stocks Lagging Hormel Foods (HRL) This Year?
Hormel Foods (HRL) is outperforming its Consumer Staples peers and its industry sector year-to-date, with a 9.8% gain compared to the sector's 8.2% average and the Food - Meat Products industry's 2.5% loss. This performance, coupled with a Zacks Rank of #2 (Buy) and rising earnings estimates, suggests a strong outlook for HRL. Kenvue (KVUE) is also highlighted as another outperforming Consumer Staples stock.
Kenvue focuses on consumer health portfolio, shares in S&P 500 peer comparison
Kenvue, a consumer health company listed on the NYSE under the ticker KVUE, is part of the S&P 500 and holds a large portfolio of everyday brands like Tylenol and Neutrogena. The company has a market capitalization of approximately $36.10 billion with 1.94 billion shares in issue, positioning it as a large-cap consumer non-cyclical stock. Kenvue competes with peers such as Haleon, Procter & Gamble, and Colgate-Palmolive, and its shares are currently trading around $18.96.
Price to earnings forward of Kenvue Inc. – NYSE:KVUE
This article provides financial information for Kenvue Inc. (NYSE: KVUE), specifically focusing on its forward price-to-earnings ratio. It indicates that the market for KVUE was closed at the time of the crawl, with no trades observed. The data is presented within the TradingView platform context.
Kenvue edges higher on NYSE, shares trade near recent range
Kenvue, the consumer health spin-off from Johnson & Johnson, saw a modest gain on the NYSE, trading near the 19 dollar mark. The stock is considered a defensive holding in the consumer staples sector, with analysts maintaining moderate price targets. Kenvue's business model relies on a broad portfolio of well-known consumer health brands.
Price to sales forward of Kenvue Inc. – NYSE:KVUE
This article provides financial information for Kenvue Inc. (NYSE: KVUE), specifically focusing on its forward price-to-sales ratio. It details the company's market status, financial overview, and related data available on TradingView. The page appears to be a stub or an entry point for detailed financial metrics.
TYLENOL® Introduces PainTalk to Break the Silence on Pain--So Relief Can Start Sooner
TYLENOL® has launched "PainTalk," a national platform aimed at normalizing conversations about pain to help people seek relief sooner. Collaborating with soccer legends Mia Hamm and Emma Sears, the initiative focuses on athlete storytelling, in-stadium activations, and social engagement using #PainTalk. TYLENOL® is also awarding $120,000 in grants to 12 athletes in partnership with the Women's Sports Foundation® to improve access to care.
Enterprise value to revenue forward of Kenvue Inc. – NYSE:KVUE
This article focuses on the "Enterprise value to revenue forward" metric for Kenvue Inc. (NYSE: KVUE). It appears to be a financial data point or analysis page from TradingView, providing information related to the company's financial performance.
Oak Family Advisors LLC Increases Position in Kenvue Inc. $KVUE
Oak Family Advisors LLC significantly increased its stake in Kenvue Inc. ($KVUE) by 35.4% in the first quarter, now holding 471,239 shares valued at $8.12 million. This increase makes Kenvue the 12th largest position in their investment portfolio. The article also highlights Kenvue's strong Q1 earnings, with EPS of $0.32 against estimates of $0.27 and a 4.5% revenue increase, alongside a declared quarterly dividend of $0.2075 per share, yielding about 4.4%.
Kenvue shares rise as Kimberly-Clark deal spread holds near 2%
Kenvue shares rose as the company traded below Kimberly-Clark's pending takeover offer, driven by recent positive earnings reports. The deal's completion in the second half of 2026 hinges on regulatory approvals, the fluctuating value of Kimberly-Clark stock, and ongoing lawsuit risks related to Tylenol. Analysts note Kenvue's stabilizing fundamentals as a bullish sign for Kimberly-Clark.
Kenvue Inc. stock rises Wednesday, outperforms market
Kenvue Inc. (KVUE) shares increased by 2.12% to $18.80 on Wednesday, outperforming the mixed market session. The Dow Jones Industrial Average rose, while the S&P 500 Index declined. This marked the second consecutive day of gains for Kenvue's stock.
SG Americas Securities LLC Sells 613,737 Shares of Kenvue Inc. $KVUE
SG Americas Securities LLC reduced its stake in Kenvue Inc. by 20.0% in the first quarter, selling 613,737 shares and retaining 2.46 million shares valued at approximately $42.4 million. Kenvue reported better-than-expected quarterly earnings with EPS of $0.32 and revenue of $3.91 billion, providing a 4.5% dividend yield despite a high payout ratio. Analysts currently rate the stock as a "Hold" with an average target price of $19.33.
The Neutrogena Ultra Sheer Dry-Touch SPF 55 from Kenvue Inc. - high protection in a light everyday l
The article reviews Neutrogena Ultra Sheer Dry-Touch SPF 55 from Kenvue Inc., highlighting its high UV protection in a lightweight, non-greasy formula suitable for daily use. It discusses the product's features, target audience, pricing, and availability, emphasizing its position within Kenvue's broader consumer health portfolio. The product is praised for its dry-touch finish and broad-spectrum coverage, making it a popular choice for those seeking comfort and protection.
Kenvue highlights dividend profile, analysts map out KVUE shares on the NYSE
Kenvue, the consumer health group spun off from Johnson & Johnson, is drawing analyst attention for its dividend profile and market valuation. Analysts generally view KVUE with a mix of Buy and Hold ratings, citing its defensive consumer-staples profile, competitive dividend yield, and strong brand portfolio including Tylenol. The company's ability to maintain brand equity and pricing power in key categories is seen as crucial for sustaining its current valuation.
Kenvue Inc. stock rises Tuesday, outperforms market
Kenvue Inc. (KVUE) shares rose 3.08% to $18.41 on Tuesday, outperforming a generally down market where the S&P 500 and Dow Jones Industrial Average both fell. Despite the day's gain, the company's stock remains 19.50% below its 52-week high of $22.87.
VanEck Morningstar Wide Moat Fund's Kenvue Inc(KVUE) Holding History
As of March 31, 2026, VanEck Morningstar Wide Moat Fund held 52,024 shares of Kenvue Inc (KVUE), valued at $896,890, representing 2.67% of its portfolio. The fund has made 5 purchases and 4 sales of KVUE shares since Q1 2024. Based on current prices and historical transactions, the fund has an estimated gain of $23,608.78 on its KVUE holdings.
Kenvue Inc. stock falls Monday, underperforms market
Kenvue Inc. (KVUE) stock slid 1.43% on Monday, closing at $17.86, underperforming the broader market. The Dow Jones Industrial Average rose, while the S&P 500 Index fell. Kenvue Inc.'s stock is currently 21.91% below its 52-week high reached in July.
Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity
Sonoma Pharmaceuticals recently announced an increase in its at-the-market equity offering capacity to $3.64 million, providing greater flexibility for accessing equity capital. The company previously sold 173,073 shares, raising $574,633 through a sales agreement with Ladenburg Thalmann & Co. TipRanks’ AI Analyst, Spark, rates SNOA as Neutral due to weak financial quality and bearish technical trends, despite some positive factors like a Kenvue supply agreement and modest leverage.
Johnson & Johnson (JNJ) Stock Could Be 7.3% Undervalued Based On Its Pharma And MedTech Focus
Johnson & Johnson (JNJ) stock is considered potentially 7.3% undervalued, with a fair value estimated at $246.46 against its last close of $228.39, due to its focus on higher-margin Pharmaceutical and MedTech segments post-Kenvue spin-off. While the P/E ratio of 26.1x is higher than the US Pharmaceuticals average, suggesting less obvious upside, the company is seen as a high-quality, defensive healthcare leader with resilient earnings and strong cash flow. Investors are advised to weigh these factors, along with risks like litigation and pricing pressures.
